Brief: Spero Therapeutics Appoints Esther Rajavelu As Chief Financial Officer And Chief Business Officer
01/11/2023 12:07
Nov 1 (Reuters) - Spero Therapeutics Inc SPRO.O :
* SPERO THERAPEUTICS APPOINTS ESTHER RAJAVELU AS CHIEF
FINANCIAL
OFFICER AND CHIEF BUSINESS OFFICER
* SPERO THERAPEUTICS INC - RAJAVELU WILL SUCCEED STEPHEN
DIPALMA,
WHO HAS SERVED AS COMPANY'S INTERIM CFO SINCE AUGUST 1, 2023.
Source text for Eikon: ID:nGNX2S9YLS
Further company coverage: SPRO.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Spero Therapeutics
See all newsBrief: Spero Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(C)(4)
Brief: Spero Therapeutics - May Offer Up To $300 Million In Securities - SEC Filing
Brief: Spero Therapeutics Appoints Debra Jeske Zack, M.D., Ph.D., As Chief Medical Officer
Spero licenses Innovent's experimental immune disease drug for up to $1.1 billion
US FDA approves GSK's oral antibiotic for drug-resistant UTIs (updated)